Gå direkt till innehåll
OnDosis completes a private placement of SEK 75 million supported by AstraZeneca and Aeternum Capital

Nyhet -

OnDosis completes a private placement of SEK 75 million supported by AstraZeneca and Aeternum Capital

OnDosis, a Swedish Life science company developing a new drug/device technology platform, announced today that the Company has completed a private placement of SEK 75 million. Investors in the private placement include OnDosis founders AstraZeneca and Martin Olovsson and major shareholders Aeternum Capital, DIG Investment and Rydgruppen

Ämnen

Kontakter